数字中医药（英文）2020，Vol.3Issue(4)：229-238,10.DOI:10.1016/j.dcmed.2020.12.001
睑板腺功能障碍的中西医物理治疗
Physical Therapy Modalities of Western Medicine and Traditional Chinese Medicine for Meibomian Gland Dysfunction
摘要
Abstract
The meibomian gland is a unique sebaceous gland located in the eyelid. Its main function is to secrete lipids and form the lipid layer of the tear film to delay the evaporation of waterborne tears, increase the surface tension of the tear film, and to lubricate the contact area of the eyelid and eyeball. Abnormal secretion of the meibomian gland is known as meibomian gland dysfunction (MGD), which has become the most important cause of evaporative dry eye disease (DED). The clinical pathophysio-logical process and underlying molecular mechanisms of MGD are not clear. As serious side effects may occur with the long-term use of hormonotherapy and non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of MGD, meibomian gland physiotherapy is considered the most effective and safest therapy for MGD. This review summarizes the physical therapy modalities of western medicine (WM) and traditiond Chinese medicine (TCM) for the treatment of MGD to provide optimal treatments for these patients and to further lay a foundation for mechanistic studies of MGD.关键词
睑板腺功能障碍/干眼病/眼睑卫生/LipiFlow/强脉冲光/针灸/眼部熏蒸/艾灸Key words
Meibomian gland dysfunction (MGD)/Dry eye disease/Eyelid hygiene/LipiFlow/Intense pulse light (IPL)/Acupuncture/Eye fumigation/Moxibustion引用本文复制引用
李洁,欧尚坤,李炜,刘祖国,彭清华..睑板腺功能障碍的中西医物理治疗[J].数字中医药（英文）,2020,3(4):229-238,10.基金项目
We thank for the funding support from the Research and Innovation Project of Graduate Students in Hunan Province(No.CX20190538),the First-class Open Fund for Integrated Chinese and Western Medicine(No.2018ZXYJH05),the Traditional Chinese Medicine First-Class Discipline Open Fund(No.2018ZYX57),and the Construction Project of Hunan Engineering Technology Research Center for the Prevention and Treatment of Otorhinolaryngo-logic Diseases and Protection of Visual Function with Chinese Medicine(No.2018YGC02). （No.CX20190538）
